SCHEMBL16835705

SCHEMBL16835705

CCCCCCCCCCCCCCCCCc1cc(CBr)cc(CBr)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.57
CYP3A4 P08684 2/20 0.54
GPR84 Q9NQS5 2/20 0.52
ESR1 P03372 2/20 0.47
ADRA2A P08913 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
TACR2 P21452 2/20 0.47
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
SHBG P04278 1/20 0.47
TP53 P04637 1/20 0.47
HSPD1 P10809 1/20 0.47
ADRB3 P13945 1/20 0.47
HTR2C P28335 1/20 0.47
HSPE1 P61604 1/20 0.47
HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28158495 1.00 PTGS2 (0.57) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL31628722 1.00 PTGS2 (0.57) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL19900643 1.00 PTGS2 (0.57) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL28295239 0.92 KCNH2 (0.50) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL9122379 0.88 PTGS2 (0.70) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL8560359 0.88 PTGS2 (0.70) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL7628223 0.88 PTGS2 (0.70) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL10474252 0.87 PTGS2 (0.63) PTGS2CYP3A4GPR84FUT7
SCHEMBL9420945 0.85 PTGS2 (0.67) PTGS2CYP3A4GPR84ESR1ADRA2A
SCHEMBL2871788 0.85 PTGS2 (0.68) PTGS2CYP3A4GPR84ESR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10155798-B2 Anti-obesity compounds derived from neuromedin U THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-12-18 US disclosed
WO-2017044592-A1 CONJUGATED ANTICANCER SMAC ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-03-16 WO disclosed
US-20170037103-A1 Anti-Obesity Compounds Derived from Neuromedin U THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-02-09 US disclosed
WO-2015095719-A1 ANTI-OBESITY COMPOUNDS DERIVED FROM NEUROMEDIN U THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037103-A1 Anti-Obesity Compounds Derived from Neuromedin U NMUR1, NMUR2, NMBR PTGS2 4438/4885CYP3A4 4852/4885GPR84 399/4885
US-10155798-B2 Anti-obesity compounds derived from neuromedin U NMUR1, NMUR2, NMBR PTGS2 4438/4885CYP3A4 4852/4885GPR84 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.